Advances in non-dopaminergic treatments for Parkinson's disease
Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has resulted in extensive...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033125/ |